CoChat
Sign Up
Cited by 200Renin-Angiotensin System StudiesBlood Pressure and Hypertension StudiesEicosanoids and Hypertension Pharmacology

Hypertension in Obese Zucker Rats: Role of Angiotensin II and Adrenergic Activity

Alonso-Galicia, Magdalena, Brands, Michael W., Zappe, Dion H., Hall, John E.·1996·Hypertension
DOI 10.1161/01.hyp.28.6.1047
Open this paper in CoChat — free account

Abstract

We designed our studies to determine whether blood pressure is elevated in obese Zucker rats compared with lean control rats and to test the importance of the renin-angiotensin and adrenergic nervous systems in long-term blood pressure control in this genetic model of obesity. We monitored mean arterial pressure 24 hours per day using computerized methods in 13- to 14-week-old lean and obese Zucker rats maintained on a fixed, normal sodium intake (3.3 mmol/d). Mean arterial pressure (average of 5 days) was higher in obese (100±1 mm Hg) than in lean (86±1) rats. Although control plasma renin activity was lower in obese than in lean rats (3.66±0.15 versus 5.48±0.11 ng angiotensin I/mL per hour), blood pressure sensitivity to exogenous angiotensin II was greater in obese than in lean rats. Blockade of endogenous angiotensin II receptors with losartan (10 mg/kg per day) for 7 days also caused a greater decrease in blood pressure in obese (36±2 mm Hg, n=6) than in lean (25±1, n=5) rats. However, combined α- and β-adrenergic blockade with terazosin (10 mg/kg per day) and propranolol (10 mg/kg per day), respectively, for 8 days caused only modest decreases in blood pressure in obese (9±3 mm Hg, n=8) and lean (4±2, n=6) rats, despite effective α- and β-adrenergic blockade. These results suggest that increased arterial pressure in obese Zucker rats depends in part on angiotensin II. However, additional mechanisms may also contribute to increased blood pressure in obese Zucker rats.

Integrity signals

Registry

Crossref · 10.1161/01.hyp.28.6.1047

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Obesity enhances blood pressure sensitivity to angiotensin II.

    “For reasons that are still unclear, obesity enhances BP sensitivity to AngII62.”

    From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [62]

  • In obese Zucker rats there is increased sensitivity to the BP effects of AngII and RAAS blockade lowers BP to a greater extent than in lean rats despite lower PRA.

    “In obese Zucker rats there is increased sensitivity to the BP effects of AngII and RAAS blockade lowers BP to a greater extent than in lean rats despite lower PRA45.”

    From Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms (2015) · cites this paper as [45]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Alonso-Galicia, M., Brands, M. W., Zappe, D. H., & Hall, J. E.
Affiliations
  • the Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson.
  • University of Mississippi Medical Center (US)
ORCID
Hall, John E.
Venue
Hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1996-12
Volume
28
Issue
6
Pages
1047-1054
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
DOI
10.1161/01.hyp.28.6.1047
OpenAlex
W2114920731
Cited by
200
References
34
Citations by year
2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 6 · 2017: 7 · 2016: 5 · 2015: 8 · 2014: 9 · 2013: 8 · 2012: 10
FWCI
2.03
Type
journal article
Language
en
Open access
closed
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01hl023502-13, 5r01hl039399-05)
  • National Heart, Lung, and Blood Institute (HL-23502, HL‐51971, HL-39399, P01HL051971)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
obesity, Zucker rats, renin-angiotensin system, angiotensin II, angiotensin II receptor, losartan, adrenergic system, alpha-adrenergic blockade, beta-adrenergic blockade, terazosin, propranolol, blood pressure regulation
MeSH terms
Adrenergic alpha-Antagonists, Angiotensin II, Animals, Antihypertensive Agents, Biphenyl Compounds, Hemodynamics, Imidazoles, Infusions, Intravenous, Kidney, Male, Obesity, Prazosin, Rats, Zucker, Renin, Renin-Angiotensin System, Sympathetic Nervous System, Tetrazoles, Sodium Chloride, Dietary, Losartan, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review